{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T07:35:31Z","timestamp":1790062531436,"version":"4.0.1"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","issue":"2","license":[{"start":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T00:00:00Z","timestamp":1602633600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CCP"],"published-print":{"date-parts":[[2020,10,14]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>2-iminobiotin (2-IB) is an investigational neuroprotective agent in development\nfor the reduction of brain cell injury after cerebral hypoxia-ischemia.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>The present first-in-human study evaluated the safety, tolerability, pharmacokinetics\n(PK) and -dynamics (PD) of 2-IB in healthy male subjects, intravenously infused with or without\nCaptisol\u00ae as a solubilizing agent.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>This randomized, double-blind, placebo-controlled, dose-escalation study was executed\nin 2 groups of 9 healthy male subjects. A single dose of 2-IB 0.6 mg\/kg or placebo was infused over\nperiods between 15 min and 4 h, and repeated doses escalating from 0.6 mg\/kg to 12 mg\/kg, or\nplacebo were infused every 4 h for 6 administrations in total.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Single and multiple doses of 2-IB up to 6 doses of 6 mg\/kg with and without Captisol\u00ae\nwere safe and well-tolerated in healthy male subjects. 2-IB proved to be a high-clearance drug with\na volume of distribution slightly exceeding total body water volume, and with linear PK that appeared\nnot to be affected by the presence of Captisol\u00ae.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Sulfobutyletherbeta-cyclodextrin (SBECD) in Captisol\u00ae had a low-clearance profile\nwith a small volume of distribution, with time-independent PK. Preliminary PD characterization of\nrepeated iv dosing of 2-IB in an acute peripheral hypoxic ischemia model in healthy subjects did\nnot reveal any notable effects of 2-IB, noting that this model was not selected to guide efficacy in\nthe currently pursued indication of cerebral hypoxia-ischemia.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1574884714666191017111109","type":"journal-article","created":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T06:27:38Z","timestamp":1571380058000},"page":"152-163","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["First-in-Human Study of the Safety, Tolerability, Pharmacokinetics and - Preliminary Dynamics of Neuroprotectant 2-Iminobiotin in Healthy Subjects"],"prefix":"10.2174","volume":"15","author":[{"given":"Ewoud-Jan","family":"van Hoogdalem","sequence":"first","affiliation":[{"name":"Scientific Affairs \u2013 Clinical Pharmacology, PRA Health Sciences, Groningen, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3982-6868","authenticated-orcid":true,"given":"Cacha M.P.C.D.","family":"Peeters-Scholte","sequence":"additional","affiliation":[{"name":"Neurophyxia B.V., 's-Hertogenbosch, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4642-7419","authenticated-orcid":true,"given":"Paul W.T.J.","family":"Leufkens","sequence":"additional","affiliation":[{"name":"Neurophyxia B.V., 's-Hertogenbosch, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0479-7817","authenticated-orcid":true,"given":"Jan","family":"Hartstra","sequence":"additional","affiliation":[{"name":"Early Development Services, PRA Health Sciences, Groningen, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9676-5136","authenticated-orcid":true,"given":"Jan J.","family":"van Lier","sequence":"additional","affiliation":[{"name":"Early Development Services, PRA Health Sciences, Groningen, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4082-7980","authenticated-orcid":true,"given":"Leo G.J.","family":"de Leede","sequence":"additional","affiliation":[{"name":"Neurophyxia B.V., 's-Hertogenbosch, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","container-title":["Current Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/175796","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,12]],"date-time":"2020-12-12T19:36:37Z","timestamp":1607801797000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/175796\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,14]]},"references-count":0,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,10,14]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1574884714666191017111109","relation":{},"ISSN":["1574-8847"],"issn-type":[{"value":"1574-8847","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10,14]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-06-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-18","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}